Earlier studies have identified various beneficial roles of Gal-1 in treating several experimental autoimmune diseases, including experimental autoimmune encephalitis, collagen-induced arthritis, concanavalin A-induced hepatitis, nephrotoxic nephritis, autoimmune diabetes, experimental autoimmune uveitis, serum-induced nephritis, and inflammatory bowel disease (31). This evidence concerns the gene LGALS1 and inflammatory bowel disease.